Arrivent Biopharma Inc SEC Filings

ArriVent BioPharma director Kristine Peterson received a new stock option grant. She was awarded a non-qualified option covering 13,562 shares of common stock at an exercise price of $31.74 per share. The option vests on the first anniversary of the grant date, contingent on her continued service, and expires on June 17, 2036. Following this grant, she holds 13,562 derivative securities directly from this award.

ArriVent BioPharma, Inc. director John Hohneker received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share, expire on June 17, 2036, and vest on the first anniversary of the June 18, 2026 grant date, subject to continued service.

ArriVent BioPharma director Chris Nolet received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036. The underlying shares vest on the first anniversary of the June 18, 2026 grant date, conditioned on continued service.

ArriVent BioPharma, Inc. reported results of its 2026 annual meeting of stockholders held via live webcast. Stockholders elected three Class II directors—James Healy, M.D., Ph.D., John Hohneker, M.D., and Stuart Lutzker, M.D., Ph.D.—to serve until the 2029 annual meeting.

Of 46,368,442 common shares eligible to vote as of April 21, 2026, 33,418,793 shares, or 72.07%, were present or represented by proxy, satisfying quorum requirements. Stockholders also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

ArriVent BioPharma, Inc. filed a prospectus supplement tied to its existing at-the-market equity offering program. Under this supplement, the company may offer and sell shares of its common stock with an aggregate offering price of up to $250,000,000 from time to time through Jefferies LLC as sales agent.

The at-the-market sales are made under an Open Market Sale Agreement dated February 3, 2025, and are covered by ArriVent’s automatic shelf registration statement on Form S-3ASR, which became effective upon filing. The company also filed the sales agreement and related legal opinions as exhibits.

ArriVent BioPharma, Inc. is offering up to $250,000,000 of its common stock in an “at the market” (ATM) program through Jefferies LLC as sales agent. Shares may be sold from time to time at market prices; Jefferies may receive commissions up to 3.0%. The prospectus supplement cites a last reported sale price of $29.50 per share (May 8, 2026), and illustrates an issuance of 8,474,576 shares at that price. The document states shares outstanding were 45,308,941 as of March 31, 2026 and presents net tangible book value of $301.1 million (or $6.64 per share) and an illustrative as‑adjusted net tangible book value of $544.7 million (or $10.12 per share) after the assumed $250.0 million ATM sale. Net proceeds are stated to be used to support development of firmonertinib, other pipeline programs and general corporate purposes. Sales under the agreement are conditional, may occur at varying prices and times, and Jefferies may terminate or decline transaction instructions per the sales agreement terms.

ArriVent BioPharma reported first-quarter 2026 results showing continued investment in its oncology pipeline and a narrower loss. Net loss was $43.3 million, compared with $64.4 million a year earlier, driven mainly by lower early-stage R&D spending.

Research and development expense fell to $37.6 million from $61.3 million, while general and administrative costs rose to $8.5 million as the company scales public-company operations. ArriVent ended March 31, 2026 with $326.4 million in cash, cash equivalents and marketable securities and believes this will fund operations for at least 12 months.

Pipeline progress included ongoing Phase 3 trials of firmonertinib in EGFR-mutant NSCLC and a Phase 1 trial of antibody-drug conjugate ARR-217. The company also raised $54.7 million net by selling 2.4 million shares via its at-the-market equity program and retains access to an undrawn $75 million term loan facility.

ArriVent BioPharma reported first quarter 2026 results and highlighted progress across its oncology pipeline. The company is running two pivotal firmonertinib Phase 3 trials in uncommon EGFR-mutant non-small cell lung cancer, with topline monotherapy data in frontline EGFR exon 20 insertion NSCLC expected in mid-2026 and the global ALPACCA PACC-mutant study continuing enrollment.

ArriVent also advanced its antibody-drug conjugate programs: ARR-002 received FDA clearance of its IND, with initial clinical development planned in ovarian and endometrial cancers, and ARR-217 continues in a Phase 1 trial for gastrointestinal tumors. Management reiterated a projected cash runway into the fourth quarter of 2027.

Financially, for the quarter ended March 31, 2026, research and development expenses were $37.6 million versus $61.3 million a year earlier, while general and administrative expenses rose to $8.5 million from $5.5 million. Net loss narrowed to $43.3 million from $64.4 million, or $0.96 per share compared with $1.90 per share. Cash and cash equivalents were $62.1 million and short-term investments were $264.3 million as of March 31, 2026.

Arrivent Biopharma Inc ownership update: FMR LLC reports beneficial ownership of 3,016,131.87 shares of Common Stock, representing 6.8% of the class as disclosed on the cover information. The filing states voting and dispositive powers held by FMR LLC and identifies Abigail P. Johnson with dispositive power over the same shares.

The filing is an amendment to a Schedule 13G/A and includes Exhibit 99 and a power of attorney reference.